This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
MEDNAX's (MD) Earnings Miss Estimates in Q1, Tumble Y/Y
by Zacks Equity Research
MEDNAX's (MD) Q1 results reflect the coronavirus adversities that drained its revenues and volumes.
Tenet Healthcare (THC) Q1 Earnings Beat Estimates, Rise Y/Y
by Zacks Equity Research
Tenet Healthcare's (THC) Q1 results reflect a strong operating performance and an income tax benefit, partly offset by the coronavirus outbreak.
Humana's (HUM) Earnings Beat Estimates in Q1, Improve Y/Y
by Zacks Equity Research
Humana's (HUM) first-quarter results reflect better revenues and growth in Medicare Advantage business.
Community Health (CYH) Q1 Earnings & Revenues Miss Estimates
by Zacks Equity Research
Community Health's (CYH) Q1 results hurt by softer revenues due to decline in admissions.
Anthem's (ANTM) Q1 Earnings Miss Estimates, Improve Y/Y
by Zacks Equity Research
Anthem's (ANTM) Q1 results reflect solid growth across Government Business, offset by weak performance of Commercial & Specialty Business and Other segments.
Universal Health (UHS) Q1 Earnings, Revenues Miss Estimates
by Zacks Equity Research
Universal Health's (UHS) first-quarter earnings reflect pre-tax unrealized loss and higher expenses.
Stock Market News for Apr 22, 2020
by Zacks Equity Research
U.S. equities ended sharply lower on Tuesday, dragging the three major benchmarks to their lowest levels in about two weeks.
HCA Holdings (HCA) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
HCA (HCA) delivered earnings and revenue surprises of -10.73% and -1.30%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
HCA Healthcare's (HCA) Earnings Miss in Q1, Decrease Y/Y
by Zacks Equity Research
HCA Healthcare's (HCA) Q1 earnings take a hit from the coronavirus outbreak inducing lower patient volumes.
HCA Healthcare (HCA) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
HCA Healthcare's (HCA) Q1 results are likely to reflect weak volumes from the coronavirus effect.
Earnings Preview: HCA Holdings (HCA) Q1 Earnings Expected to Decline
by Zacks Equity Research
HCA (HCA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MEDNAX Plunges More Than 54% YTD: Will the Stock Rebound?
by Zacks Equity Research
Even though MEDNAX (MD) endures the COVID-19 impact on global economy, it holds high prospects to revive its fortunes by virtue of its solid fundamentals.
MEDNAX Provides Updates Related to Coronavirus Pandemic
by Zacks Equity Research
MEDNAX (MD) takes several steps to help fight the COVID-19 pandemic.
Community Health Repeals 2020 Outlook Amid Coronavirus Woes
by Zacks Equity Research
Community Health (CYH) withdraws its current-year guidance amid prevalent market volatility induced by the COVID-19 spread.
HCA Healthcare, Google Cloud Tie Up Amid Coronavirus Woes
by Zacks Equity Research
HCA Healthcare (HCA) partners Google Cloud and SADA for the COVID-19 National Response Portal, a platform to provide real-time COVID-19 updates.
Select Medical Revokes Full-Year View Amid Coronavirus Blues
by Zacks Equity Research
Plagued by business uncertainty from the coronavirus outbreak, Select Medical (SEM) ditches its 2020 earnings guidance.
Tenet Healthcare (THC) Gets Rating Actions From Moody's
by Zacks Equity Research
Tenet Healthcare (THC) gets specific rating actions from credit rating agency Moody's. The outlook of the ratings is stable.
HCA Healthcare Makes Cost-Control Efforts Amid Coronavirus Woes
by Zacks Equity Research
HCA Healthcare (HCA) trims headcount to contain costs as its revenues are under pressure.
Tenet Heathcare Scraps Q1 & 2020 Guidance Amid Coronavirus Chaos
by Zacks Equity Research
Tenet Heathcare (THC) nullifies its first-quarter and 2020 outlook due to the COVID-19 pandemic.
HCA Healthcare Plunges Above 39% Year to date: Here's Why
by Zacks Equity Research
HCA Healthcare (HCA) stock plunges due to halt in elective surgeries, exorbitant costs and an escalating leverage level.
MEDNAX Withdraws Q1 & 2020 Guidance Due to Coronavirus Woes
by Zacks Equity Research
MEDNAX (MD) takes back its first-quarter 2020 and preliminary full-year outlook due to the COVID-19 effect.
Coronavirus-Hit Hospital Stocks Gain on Senate Stimulus Help
by Sapna Bagaria
The stimulus bill will offer the much-required financial relief to COVID-19-plagued hospitals and lead to their share price appreciation.
Acadia Healthcare Cancels U.K. Unit Sale on Coronavirus Crisis
by Zacks Equity Research
Acadia Healthcare (ACHC) dismisses plan to sell its U.K. business due to the economic uncertainty caused by coronavirus outbreak.
Tenet Healthcare Down 60.6% YTD: Should You Buy the Dip?
by Zacks Equity Research
Tenet Healthcare (THC) stock down following recommendations to keep elective procedures on hold due to coronavirus outbreak.
Chips Are Down for Hospitals on Coronavirus-Led Business Woes
by Sapna Bagaria
Stocks of hospital companies display a persistent downtrend as they put elective procedures on a back burner to brace up for the fight against a potential spike in coronavirus cases.